RCM
SGMO

Raleigh Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Raleigh Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,519
Closed -$2.46K – 1153
2023
Q4 		$2.46K Buy
+4,519
New +$2.08K ﹤0.01% 846

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raleigh Capital Management's SGMO Position: Q1 2024 in Review

Raleigh Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2024, closing a stake of 4,519 shares — an estimated $2.46K sold.

Raleigh Capital Management first reported a position in SGMO in Q4 2023 and held it in 1 quarter. The position peaked at $2.46K in Q4 2023. 131 funds tracked by Wall St. Rank hold SGMO as of Q1 2024.

  • Raleigh Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 4,519 SANGAMO THERAPEUTICS INC shares in Q1 2024, an estimated $2.46K.
  • Raleigh Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2023 and held it in 1 quarter.
  • Raleigh Capital Management's SANGAMO THERAPEUTICS INC position peaked at $2.46K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.